SCMP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SCMP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for Sucampo Pharmaceuticals's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sucampo Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | |||||||||||
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | 97.84 | 58.94 | 53.64 |
Sucampo Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | |
Shiller PE Ratio | Get a 7-Day Free Trial | 52.73 | 53.64 | 41.62 | - | - |
For the Drug Manufacturers - Specialty & Generic subindustry, Sucampo Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Sucampo Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Sucampo Pharmaceuticals's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Sucampo Pharmaceuticals's E10 for the quarter that ended in Sep. 2017 is calculated as:
For example, Sucampo Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2017 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Sep. 2017 (Change) | * | Current CPI (Sep. 2017) |
= | 0.19 | / | 104.1356 | * | 104.1356 | |
= | 0.190 |
Current CPI (Sep. 2017) = 104.1356.
Sucampo Pharmaceuticals Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
200712 | -0.030 | 88.616 | -0.035 |
200803 | 0.010 | 90.090 | 0.012 |
200806 | 0.710 | 92.320 | 0.801 |
200809 | -0.060 | 92.307 | -0.068 |
200812 | -0.080 | 88.697 | -0.094 |
200903 | -0.040 | 89.744 | -0.046 |
200906 | -0.010 | 91.003 | -0.011 |
200909 | 0.000 | 91.120 | 0.000 |
200912 | 0.160 | 91.111 | 0.183 |
201003 | 0.040 | 91.821 | 0.045 |
201006 | 0.000 | 91.962 | 0.000 |
201009 | 0.050 | 92.162 | 0.056 |
201012 | -0.160 | 92.474 | -0.180 |
201103 | -0.170 | 94.283 | -0.188 |
201106 | -0.220 | 95.235 | -0.241 |
201109 | -0.100 | 95.727 | -0.109 |
201112 | 0.070 | 95.213 | 0.077 |
201203 | -0.050 | 96.783 | -0.054 |
201206 | -0.020 | 96.819 | -0.022 |
201209 | -0.140 | 97.633 | -0.149 |
201212 | 0.330 | 96.871 | 0.355 |
201303 | -0.080 | 98.209 | -0.085 |
201306 | 0.150 | 98.518 | 0.159 |
201309 | 0.040 | 98.790 | 0.042 |
201312 | 0.050 | 98.326 | 0.053 |
201403 | 0.020 | 99.695 | 0.021 |
201406 | 0.040 | 100.560 | 0.041 |
201409 | 0.030 | 100.428 | 0.031 |
201412 | 0.200 | 99.070 | 0.210 |
201503 | 0.140 | 99.621 | 0.146 |
201506 | 0.210 | 100.684 | 0.217 |
201509 | 0.160 | 100.392 | 0.166 |
201512 | 0.220 | 99.792 | 0.230 |
201603 | -0.100 | 100.470 | -0.104 |
201606 | -0.020 | 101.688 | -0.020 |
201609 | 0.190 | 101.861 | 0.194 |
201612 | 0.350 | 101.863 | 0.358 |
201703 | 0.100 | 102.862 | 0.101 |
201706 | -3.920 | 103.349 | -3.950 |
201709 | 0.190 | 104.136 | 0.190 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Sucampo Pharmaceuticals (NAS:SCMP) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Sucampo Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Greenleaf | officer: Chief Executive Officer | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Maureen Oconnell | director | |
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Jones W. Bryan | officer: Sr. Vice Pres., BD & Licensing | C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850 |
Robert J. Spiegel | director | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Timothy P Walbert | director | 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062 |
Peter A Kiener | officer: Chief Science Officer | 40 GUEST STREET, BOSTON MA 02135 |
John Johnson | director | DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101 |
Peter P. Pfreundschuh | officer: CFO | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Paul R Edick | director | C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010 |
Thomas J Knapp | other: Former Officer | 4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239 |
William Ashton | director | C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073 |
Timothy I Maudlin | director | 18739 VOGEL FARM TRAIL, EDEN PRAIRIE MN 55347 |
Nantahala Capital Management, Llc | 10 percent owner | 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840 |
Mariam E Morris | officer: Chief Acctg. Officer, Treas. | C/O SUCAMPO PHARMACEUTICALS, 4520 EAST-WEST HIGHWAY, SUITE 300, BETHESDA MD 20814 |
From GuruFocus
By gurufocus 10qk • 05-10-2010
By gurufocus • 08-08-2009
By gurufocus 10qk • 08-05-2010
By gurufocus 10qk • 03-08-2011
By gurufocus 10qk • 11-06-2009
By Omar Venerio Omar Venerio • 11-01-2017
By reports.droy reports.droy • 03-04-2015
By gurufocus 10qk • 11-03-2010
By alicet236 alicet236 • 10-21-2013
By gurufocus • 05-12-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.